Lonza Group AG Stock price

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 07:09:10 2024-03-19 am EDT 5-day change 1st Jan Change
476.7 CHF -0.27% Intraday chart for Lonza Group AG +4.06% +34.89%
Sales 2023 6.72B 7.55B Sales 2024 * 6.61B 7.43B Capitalization 35.51B 39.92B
Net income 2023 654M 735M Net income 2024 * 885M 995M EV / Sales 2023 4.05 x
Net Debt 2023 922M 1.04B Net Debt 2024 * 2.2B 2.47B EV / Sales 2024 * 5.71 x
P/E ratio 2023
39.8 x
P/E ratio 2024 *
38.9 x
Employees 18,000
Yield 2023
1.13%
Yield 2024 *
0.95%
Free-Float 96.94%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.49%
1 week+4.32%
Current month+3.46%
1 month+4.57%
3 months+39.60%
6 months+12.66%
Current year+35.14%
More quotes
1 week
458.90
Extreme 458.9
484.80
1 month
447.50
Extreme 447.5
484.80
Current year
339.00
Extreme 339
484.80
1 year
308.60
Extreme 308.6
599.40
3 years
308.60
Extreme 308.6
785.40
5 years
282.20
Extreme 282.2
785.40
10 years
81.25
Extreme 81.25
785.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 17-04-24
Director of Finance/CFO 52 21-11-30
Chief Operating Officer 55 22-07-31
Members of the board TitleAgeSince
Director/Board Member 63 14-04-15
Director/Board Member 66 14-04-15
Director/Board Member 58 22-05-04
More insiders
Date Price Change Volume
24-03-19 476.7 -0.27% 28 724
24-03-18 478 +0.84% 148,453
24-03-15 474 -1.92% 577,590
24-03-14 483.3 +2.57% 284,081
24-03-13 471.2 +2.77% 253,304

Delayed Quote Swiss Exchange, March 18, 2024 at 12:31 pm EDT

More quotes
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
478 CHF
Average target price
524.4 CHF
Spread / Average Target
+9.70%
Consensus
  1. Stock
  2. Equities
  3. Stock Lonza Group AG - Swiss Exchange